Roivant Sciences Ltd. (ROIV) 今日盘中股价大幅上涨5.02%，引起了市场的关注。
消息面上，公司旗下Priovant Therapeutics公司宣布，其试验药物brepocitinib在针对皮肤结节病的二期研究中显示出积极成果。研究数据显示，在较高剂量下，患者的皮肤活动性得到显著改善。此外，公司另一家子公司Pulmovant也已完成针对肺动脉高压的实验性药物mosliciguat的二期试验患者招募工作。这些临床试验的积极进展增强了市场对公司研发管线前景的信心。
Priovant表示，计划在与美国食品药品监督管理局（FDA）协商后，于2026年启动brepocitinib的第三阶段试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.